Tirzepatide

Generic Name: Tirzepatide

Brand Names: Mounjaro

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2023788-19-2

Unique Ingredient Identifier: OYN3CCI6QE

Background: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...

Indication: Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Tirzepatide
Drug: Insulin Glargine

First Posted Date: 2018-11-05

Last Posted Date: 2022-02-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2002

Registration Number: NCT03730662

Locations: 🇵🇱
Woj. Zesp. Spec. Opieki Zdrowotnej, Wroclaw, Poland
🇺🇸
Northwestern Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Preferred Primary Care Physicians- Bower Hill, Pittsburgh, Pennsylvania, United States

and more 205 locations

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

Phase 1

Completed

Conditions: End Stage Renal Disease
Renal Insufficiency

Interventions: Drug: Tirzepatide

First Posted Date: 2018-03-29

Last Posted Date: 2023-03-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 45

Registration Number: NCT03482024

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

and more 1 locations

A Study of Tirzepatide (LY3298176) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2017-12-18

Last Posted Date: 2024-02-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT03375463

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2017-10-26

Last Posted Date: 2023-03-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT03322631

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Tokyo, Japan

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2017-10-17

Last Posted Date: 2021-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 111

Registration Number: NCT03311724

Locations: 🇺🇸
Valley Research, Fresno, California, United States
🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States

and more 10 locations

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: tirzepatide
Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2017-04-27

Last Posted Date: 2019-08-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 318

Registration Number: NCT03131687

Locations: 🇸🇰
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Trenčín, Slovakia
🇸🇰
"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Trenčín, Slovakia
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 38 locations

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Phase 1

Completed

Conditions: Healthy
Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: Placebo
Drug: Tirzepatide
Drug: Dulaglutide

First Posted Date: 2016-05-03

Last Posted Date: 2024-01-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 142

Registration Number: NCT02759107

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇺🇸
Miami Research Associates, South Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy